Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Viewpoints_Atray Dixit
PharmaShots Interview: Coral Genomics’s Atray Dixit Shares Insights on the 2021 Innovation Challenge in Inflammatory Bowel Disease
In an interview with PharmaShots, Atray Dixit, Co-founder & CEO at Coral Genomics share his views on the winner of the $25K inflammatory bowel disease innovation challenge under the collaboration with Lyfebulb and Arena Shots: Lyfebulb and Arena collaborated to discover 2021 Imagining Life Without Limits Challenge to get the solutions for patients with IBD Coral Genomics was selected as…
December 7, 2021
Viewpoints_Ben Schlatka
PharmaShots Interview: Medidata’s Ben Schlatka Shares Insights on Agreement with Labcorp to Advance the Use of Medical-Grade Sensors
In an interview with PharmaShots, Ben Schlatka, Vice President, Digital Biomarker Solutions at Medidata share his views on the Agreement with Labcorp to expand decentralized clinical trial capabilities and digital biomarker discovery using Medidata Sensor Cloud Shots: The companies collaborated to advance the use of medical-grade sensors & accelerate biomarker discovery in clinical research including an at-home version of 6MWT…
December 6, 2021
Viewpoints_Dr. Murat Kalayoglu
PharmaShots Interview: Cartesian Therapeutics’s Dr. Murat Kalayoglu Shares Insight on RNA Cell Therapy for an Autoimmune Disease
In an interview with PharmaShots, Dr. Murat Kalayoglu, MD, Ph.D., President, and Chief Executive Officer at Cartesian Therapeutics shared his insights on the P-I/IIa study of Descartes-08 for the treatment of the chronic autoimmune disorder generalized myasthenia gravis (gMG) Shots: Descartes-08 is an autologous T-cell product that is engineered with RNA to encode for CAR The company focuses to use…
December 1, 2021
Viewpoints_Mark Becker
PharmaShots Interview: Vivacare’s Mark Becker Shares Insight on the Digital Patient Education Service for Allergic Conditions
In an interview with PharmaShots, Mark Becker, MD, founder, President, and CEO at Vivacare shared his views on the new collaboration with Asthma and Allergy Network to provide a Digital patient education service for allergic conditions Shots: Vivacare and the AAN collaborated to develop a digital patient education service for members regarding allergies, asthma, eczema, and…
November 30, 2021
Viewpoints_Kathryn Lang
PharmaShots Interview: Guardant Health’s Kathryn Lang Shares Insight on the Data of Guardant360 Liquid Biopsy Test for the Treatment of Advanced Non-Small Cell Lung Cancer
In an interview with PharmaShots, Kathryn Lang, Vice President, Outcomes & Evidence at Guardant Health shared her views on the data from the VALUE study of Guardant360 liquid biopsy test for NSCLC Shots: The VALUE study evaluates the clinical outcomes & utility of liquid biopsy vs tissue biopsy testing in patients with NSCLC across six Canadian centers In an initial diagnosis, patients treated…
November 29, 2021
Viewpoints_Wehkamp Shares
PharmaShots Interview: Janssen’s Jan Wehkamp Shares Insight on the Data of Stelara (ustekinumab) for IBD and other Approved Indications and Presented 13 Abstracts at UEGW
In an interview with PharmaShots, Jan Wehkamp, M.D., Vice President, Gastroenterology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development shared his views on the data from 13 P-II & III studies of Stelara (ustekinumab) for the treatment of IBD and other approved indications Shots: The company has reported the data from 13 P-II & III studies, including 6 studies…
November 24, 2021
Viewpoints_Daniel A. de Boer
PharmaShots Interview: ProQR’s Daniel A. de Boer Shares Insight on Sepofarsen for the Treatment of Leber Congenital Amaurosis (LCA10)
In an interview with PharmaShots, Daniel A. de Boer, Founder, and CEO at ProQR shared his views on the P-II/III Illuminate study of sepofarsen for the treatment of leber congenital amaurosis (LCA10) Shots: The ongoing P-II/III Illuminate study evaluates sepofarsen in 36 adults and children aged ≥8yrs. with LCA10. The results are expected in late Q1 or early Q2’22 In the P-I/II clinical…
November 23, 2021
Viewpoints_Chris Arendt
PharmaShots Interview: Takeda’s Chris Arendt Shares Insight on the Data of Alunbrig Presented at ESMO 2021
In an interview with PharmaShots, Chris Arendt, Head of the Oncology Therapeutic Area Unit at Takeda shared his views on the new data of Alunbrig in the P-III ALTA-1L study for the Treatment of ALK+ mNSCLC Shots: The P-III ALTA-1L study evaluates Alunbrig vs Crizotinib in patients with ALK+ mNSCLC who have not received prior treatment with an ALK inhibitor The results showed…
November 22, 2021
Viewpoints_Paul Brennan
PharmaShots Interview: NervGen’s Paul Brennan Shares Insights on NVG-291 and its Interim Data for the Treatment of Neurodegenerative Diseases
In an interview with PharmaShots, Paul Brennan, President, CEO & Director at NervGen shared his views on the interim data of NVG-291 for the treatment of Neurodegenerative Diseases Shots: The P-I clinical trials evaluate NVG-291 vs PBO in healthy volunteers with neurodegenerative diseases such as AD and MS. The interim results were presented at ANA 146th annual meeting The interim…
November 17, 2021
Viewpoints_Christopher J. Calhoun
PharmaShots Interview: Paracrine’s Christopher J. Calhoun Shares Insight on the First Autologous, Device-Based Cell Therapy Platform
In an interview with PharmaShots, Christopher J. Calhoun, President & CEO at Paracrine shared his views on the transforming diabetes treatment with the first autologous, device-based cell therapy platform Shots: The company has developed the first autologous, device-based cell therapy platform which is ideally positioned to address conditions with underlying integers Paracrine is a one-time, completely natural procedure that…
November 16, 2021
Load more